Chronopharmacokinetics of tacrolimus in kidney transplant recipients: Occurrence of acute rejection

Journal of Clinical Pharmacology

Volumn 43, Issue 8, 2003, Pages 859-865

  Tada, Hitoshi ^a   Satoh, Sigeru ^b   Iinuma, Masahiro ^b   Shimoda, Naotake ^b   Murakami, Miho ^c   Hayase, Yukitoshi ^c   Kato, Tetsuro ^b   Suzuki, Toshio ^a  

^a AKITA UNIVERSITY HOSPITAL   (Japan)

^b AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c HOKKAIDO INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

Bioavailability; Circadian variation; Kidney transplant patient; Rejection; Tacrolimus

Indexed keywords

MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; AREA UNDER THE CURVE; ARTICLE; CHRONOPHARMACOLOGY; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; MALE; MEAN RESIDENCE TIME; TIME TO PEAK CONCENTRATION;

ADULT; AGED; AREA UNDER CURVE; CIRCADIAN RHYTHM; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE PERIOD; TACROLIMUS;

EID: 0038298287     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270003254797     Document Type: Article

References (41)

1. Reinberg A, Halberg F: Circadian chronopharmacology. Annu Rev Pharmacol 1971;11:455-492.
2. Labrecque G, Belanger PM: Biological rhythms in the absorption, distribution metabolism and excretion of drugs. Pharmacol Ther 1991;52:95-107.
3. Lemmer B: Relevance for chronopharmacology in practical medicine. Semin Perinatol 2000;24:280-290.
4. Reinberg AE, Soudant E, Koulbanis C, Bazin R, Nicolai A, Mechkouri M, et al: Circadian dosing dependency in the forearm skin penetration of methyl and hexyl nicotine. Life Sci 1995;57:1507-1513.
5. King DP, Zhao Y, Sangoram AM, Wilsbacher LD, Tanaka M, Antoch MP, et al: Positional cloning of the mouse circadian clock gene. Cell 1977;89:641-653.
6. Lavery DJ, Lopez-Molina L, Margueron R, Fleury-Olera F, Conquet F, Schibler U, et al: Circadian expression of the steroid 15 α-hydroxylase (Cyp2a4) and Coumarin 7-hydroxylase (Cyp2a5) genes in mouse liver is regulated by the PAR leucine zipper transcription factor DBP. Mol Cell Biol 1999;19:6488-6499.
7. Goto T, Kino T, Hatanaka H, Nishiyama M, Okuhara M, Kohsaka M, et al: Discovery of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubuensis. Transplant Proc 1987;19:4-8.
8. Jusko WJ: Analysis of tacrolimus (FK506) in relation to therapeutic drug monitoring. Ther Drug Monit 1995;17:596-601.
9. Ihara H, Shinkuma D, Ichikawa Y, Nojima M, Nagano S, Ikoma F: Intra- and interindividual variations in the pharmacokinetics of tacrolimus (FK506) in kidney transplant recipients: importance of trough levels as a practical indicator. Int J Urol 1995;2:151-155.
10. McAlister VC, Mahalati K, Peltekian KM, Fraser A, MacDonald AS: A clinical pharmacokinetic study of tacrolimus and sirolimus combination immunosuppression comparing simultaneous to separated administrations. Ther Drug Monit 2002;24:346-350.
11. Felipe CR, Silva HT, Machado PG, Garcia R, da Silva Moreira SR, Pestana JO: The impact of ethnic miscegenation on tacrolimus clinical pharmacokinetics and therapeutic drug monitoring. Clin Transplant 2002;16:262-272.
12. Jorgensen K, Povlsen J, Madsen S, Madsen M, Hansen H, Pedersen A, et al: C2 (2-h) levels are not superior to trough levels as estimates of the area under the curve in tacrolimus-treated renal-transplant patients. Nephrol Dial Transplant 2002;17:1487-1490.
13. Filler G, Grygas R, Mai I, Stolpe H, Greiner C, Bauer S, et al: Pharmacokinetics of tacrolimus (FK 506) in children and adolescents with renal transplants. Nephrol Dial Transplant 1997;12:1668-1671.
14. Kimikawa M, Kamoya K, Toma H, Teraoka S: Effective oral administration of tacrolimus in renal transplant recipients. Clin Transplant 2001;15:324-329.
15. Grevel J, Welsh MS, Kahan BD: Area under the curve monitoring is superior to trough level monitoring. Ther Drug Monit 1989;11:246-248.
16. Min DI, Chen H-Y, Fabrega A, Ukah FO, Wu YM, Corwin C, et al: Circadian variation of tacrolimus disposition in liver allograft recipients. Transplantation 1996;62:1190-1192.
17. Min DI, Chen H-Y, Lee M-L, Ashton K, Martin MF: Time-dependent disposition of tacrolimus and its effect on endothelin-1 in liver allograft recipients. Pharmacotherapy 1997;17:457-463.
18. Born J, Lange T, Hansen K, Molle M, Fehm H-L: Effect of sleep and circadian rhythm on human circulating immune cells. J Immunol 1997;158:4454-4464.
19. Goldsmith MA, Greene WC: Interleukin-2 and the interleukin-2 receptor, in: Thomson A (ed.), The Cytokine Handbook. London: Academic Press, 1994;57-80.
20. Uthgenannt D, Schoolmann D, Pietrosky R, Fehm HL, Born J: Effects of sleep on the release of cytokines in humans. Psychosom Med 1995;57:97-104.
21. Lemmer B: Chronopharmacokinetics: implications for drug treatment. J Pharm Pharmacol 1999;51:887-890.
22. Lemmer B, Nold G: Circadian changes in estimated hepatic blood flow in healthy subjects. Br J Clin Pharmacol 1991;32:627-629.
23. Goo RH, Moore JG, Greenberg E, Alazraki NP: Circadian variation in gastric emptying of meals in humans. Gastroenterology 1987;93:515-518.
24. Bekersky I, Dressler D, Mekki Q: Effect of time of meal consumption on bioavailability of a single oral 5 mg tacrolimus dose. J Clin Pharmacol 2001;41:289-297.
25. Wong SHY: Therapeutic drug monitoring for immunosuppressants. Clinico Chimica Acta 2001;313:241-253.
26. Hawley CM, Wall DR, Johnson DW, Campbell SB, Griffin AD, Rigby RJ, et al: Recovery of gastrointestinal function after renal transplantation in a patient with sclerosing peritonitis secondary to continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1995;26:658-661.
27. Fujimura A, Ebihara A: Administration time-dependent toxicity of a new immunosuppressive agent, tacrolimus (FK 506). Life Sci 1994;55:485-490.
28. Fujimura A, Shiga T, Ohashi K, Ebihara A: Chronopharmacokinetic study of a new immunosuppressive agent, FK 506, in mice. Jpn J Pharmacol 1993;61:137-139.
29. Uchida H, Kobayashi E, Ogino Y, Mizuta K, To H, Okabe R, et al: Chronopharmacology of tacrolimus in rats: toxicity and efficacy in a mouse-to-rat intestinal transplant model and its pharmacokinetic profile. Transplant Proc 1999;31:2751-2753.
30. Pirsch J, Bekersky I, Vincenti F, Boswell G, Woodle ES, Alak A, et al: Coadministration of tacrolimus and mycophenolate mofetil in stable kidney transplant patients: pharmacokinetics and tolerability. J Clin Pharmacol 2000;40:527-532.
31. Undre NA, Hooff J, Christiaans M, Vanrenterghem Y, Donck J, Heeman U, et al: Pharmacokinetics of FK 506 and mycophenolic acid after the administration of a FK 506-based regimen in combination with mycophenolate mofetil in kidney transplantation. Transplant Proc 1998;30:1299-1302.
32. Hochleitner BW, Bosmuller C, Nehoda H, Fruhwirt M, Simma B, Ellemunter H, et al: Increased tacrolimus levels during diarrhea. Transpl Int 2001;14:230-233.
33. Iwasaki K, Matsuda H, Nagase K, Shiraga T, Tokuma Y, Uchida K: Effects of twenty-three drugs on the metabolism of FK506 by human liver microsomes. Res Commun Chem Pathol Pharmacol 1993;82:209-216.
34. Tada H, Yanagiwara S, Itoh K, Suzuki T: Role of diltiazem on tacrolimus pharmacokinetics in tacrolimus-induced nephrotoxic rats. Pharmacol Toxicol 1999;84:241-246.
35. Regazzi MB, Iacona I, Alessiani M, Spada M, Vaccarisi S, Villani P, et al: Interaction between FK506 and diltiazem in an animal model. Transplant Proc 1996;28:1017-1018.
36. Hebert MF, Lam AY: Diltiazem increases tacrolimus concentration. Ann Pharmacother 1999;33:680-682.
37. Bailey DG, Spence JD, Munoz C, Arnold JM: Interaction of citrus juices with felodipine and nifedipine. Lancet 1991;337:268-269.
38. Di Marco MP, Edwards DJ, Wainer IW, Ducharme MP: The effect of grapefruit juice and Seville orange juice on the pharmacokinetics of dextromethorphan: the role of gut CYP3A and P-glycoprotein. Life Sci 2002;71:1149-1160.
39. Wong KM, Shek CC, Chau KF, Li CS: Abbreviated tacrolimus area-under-the-curve monitoring for renal transplant recipients. Am J Kidney Dis 2000;35:660-666.
40. Ku Y-M, Min DI: An abbreviated area-under-the-curve monitoring for tacrolimus in patients with liver transplants. Ther Drug Monit 1998;20:219-223.
41. Knapp MS, Cove-Smith JR, Dugdale R, Mackenzie N, Pownall R: Possible effect of time on renal allograft rejection. Br Med J 1979;1:75-77.